A Phase 3, randomised, double-blind study of adjuvant immunotherapy with Nivolumab versus placebo after complete resection of stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 76K).

  • Brady, Benjamin (Primary Chief Investigator (PCI))
  • Baker, Emma (Project Manager)

Project: Research

Project Details

Effective start/end date1/04/2031/12/22


  • Medical oncology
  • Melanoma
  • Clinical trial